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INTRODUCTION 
TUBERCULOSIS:        
           Tuberculosis (TB), is the communicable  disease that caused by the bacterium 
Mycobacterium tuberculosis, remains a major public health problem globally. In 2014, more 
than 9.6 million people are estimated to have fallen ill with TB while 1.5 million people died of 
the disease.  
            The disease is closely associated with poverty, which explains the high rates of TB  in 
geographic areas within countries where poverty rates are high. The disease is closely associated 
with with HIV which has been the major factor for the high rates of TB in many countries [1-2] 
 
 LONG TERM COMPLICATIONS OF TB : 
 
           Pulmonary TB is associated with various long term lung complications including lung 
scarring (fibrosis), bronchiectasis, Chronic Pulmonary Aspergillosis (CPA), air way stenosis and 
Chronic Obstructive Pulmonary Disease (COPD)  and it may even be a risk factor for lung 
cancer.[3-4] 
THE ETIOLOGICAL AGENT: 
 
         The Mycobacterium tuberculosis complex includes strains of five species—M. 
tuberculosis, M. canettii, M. africanum, M.microti, and M. bovis and two subspecies—M. 
caprae andM. pinnipedii . The most notable member of the complex is M. tuberculosis the 
causative agent of human tuberculosis which has an exclusive tropism for this host.[5-8] 
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Fig No:1 Mycobacterium tuberculosis 
 
EPIDEMIOLOGY: 
 
          Epidemiology is the study of distribution of disease in society and the factors affecting this 
distribution. 
           The epidemiology of tuberculosis varies substantially around the world. The highest rates 
(100/100,000 or higher) are observed in sub-Saharan Africa, India, China, and the islands of 
Southeast Asia and Micronesia Estimates provided by USAID in 2007 for South Sudan were 228 
cases per 100,000 population. In South Sudan, an estimated 18,500 people develop TB, and 
5,300 die of TB annually [9].  
             Poverty, HIV and drug resistance are major contributors to the resurging global TB 
epidemic. Approximately 95% of TB cases occur in developing countries. Approximately 1 in 14 
new TB cases occur in individuals who are infected with HIV; 85 percent of these cases occur in 
Africa. An estimated half million cases of multidrug resistant (MDR)-TB also occur annually in 
Africans; even higher rates of drug resistant disease occur in Eastern Europe[10] 
 
BURDEN OF TB IN INDIA: 
 According to WHO 2009 reports, estimated prevalence of TB in India is 3.3 million 
cases. 
 India is the highest TB burden country, an annual 1.98 million incident cases in India. 
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 In India annual death due to TB is 2,760000. In India death rate due to TB is 1 death per 
minute. 
 In India 2.31 million population living with HIV and 0.9 million population co infected .  
 
 
CURRENT TREATMENT AGAINST TUBERCULOSIS: 
 
          The course of TB treatment based on the stage of infection. TB is usually treated using 
multiple drugs together in a mixture, with an intensive 2-month initial phase followed by a 4 to 
6 -month continuation phase.[11] 
          Isoniazid (INH), Rifampin (RIF), Pyrazinamide (PZA), and either Ethambutol (EMB) or 
Streptomycin (SM) are usually the drugs of choice for the treatment of TB.23,24. A drug regimen 
chart created by the Centers for Disease Control and Prevention (CDC) outlines the intervals 
and doses for drug treatment during the specific phases. [12]  
          For example, if the MTB isolate is fully susceptible, either EMB or (Streptomycin) SM 
are discontinued, and PZA can be discontinued after two months of treatment. INH and RIF are 
continued for four months. Treatment can last from six to nine months, or even up to twenty 
months. [13] 
.       TB remains a prominent global health issue and the rise of multidrug-resistant (MDR)  and 
extensively drug-resistant (XDR) (MDR with added resistance to a fluoroquinolone and an 
injectable second line agent) strains, and the lack of new effective drugs is of major concern.[14] 
M. Tuberculosis develops drug resistance exclusively through chromosomal mutations, in 
particular singlenucleotide polymorphisms and a few through gene environment interaction.[15] 
 
MULTI DRUG RESISTANCE TB :   
      
        The drug resistant strains can then spread from person to person like drug susceptible 
bacteria. Strains of M. tuberculosis that are resistant against isoniazid and rifampicin, the most 
effective drugs against tuberculosis, are defined as multi drug resistant(MDR-TB).  
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             In 2006 the WHO released the first data on extensively drug resistant strains (XDR-TB). 
These strains are resistant to any fluoroquinolones and at least to one of the injectable drugs 
kanamycin, capreomycin and amikacin, in addition to  isoniazid and rifampicin and occur in 
every part of the world. Patients infected with XDR-TB are virtually untreatable with current 
drugs[1] 
 
DIAGNOSIS OF TUBERCULOSIS: 
 
1.Microbiological tests: 
2. Immunological tests:  
(a) ALS (Antibodies from lymphocyte secretions) assay- this is an immunological assay to detect 
active diseases like tuberculosis, cholera, typhoid etc. [6] 
(b) Mantoux test (MT)/Tuberculin Skin Test (TST)- positive test indicates infection by TB 
bacilli, doesn't exclude active disease cases from latent cases and inconclusive in BCG 
vaccinated people.  
3. Adenosin Deaminase Assay (ADA) test: 
 ADA is an enzyme which contributes in purin metabolism and converts adenosine to inosine. 
ADA is essential for proliferation and differentiation of lymphoid cells, especially T cells, and 
helps in the maturation of monocytes to macrophages. It seems ADA is an index for cellular 
immunity. Activity of this enzyme increases in TB, empyema, lymphoma and other chronic 
inflammatory conditions like Rheumatoid Arthritis (RA). [17] 
Need for new anti-TB drugs: 
 To  improve the treatment of MDR-TB. 
 To improve current treatment by shortening the total duration of the treatment. 
 The recent rise in TB cases and especially the increase of drug resistant mycobacteria 
indicate an urgent need to develop new anti-TB drugs. 
 There is a need to design new drugs that are more active against slowly growing and 
nongrowing persistent bacilli. 
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 Discovery of compound that would reduce both the length of treatment and the frequency 
of drug administration. 
 To provide more effective treatment for latent tuberculosis infection. 
New drug to improve current that would reduce both the total length of treatment and the 
frequency of drug administration.  
ENZYME PROFILE: 
      Among the most attractive molecular targets to the design of novel antibacterial agents are 
the Fatty Acid Synthase (FAS) pathway enzymes. The Mycobacterium tuberculosis InhA 
(MtInhA) or 2-trans-enoyl-ACP (CoA) reductase , the fourth enzyme of the type II fatty acid 
synthase system (FAS II), is one of the key enzymes involved in the elongation cycle of fatty 
acids in M. tuberculosis. 
        Its biological role includes the preferentially reduction of long chain enoyl thioester 
substrates (e.g., containing 16 or more carbon atoms) yielding the long carbon chain of the 
meromycolate branch of mycolic acids (C40−60), α-branched fatty acids, the hallmark of 
mycobacteria.8 Previously, it has been shown that InhA is essential to the mycolic acid 
biosynthesis in Mycobacterium.[18] 
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Fig No 2:  InhA( Enoyl Acyl Carrier Protein Reductase) 
 
ENZYME NAME                 :   ENOYL-ACP REDUCTASE 
CLASSIFICATION    :   OXIDO REDUCTASE 
POLYMER     :   1 
TYPE                                     :   Protein 
CHAINS                               :   A, B 
ORGANISM                         :   Mycobacterium tuberculosis 
PROTEOME                        : Chromosome 
FUNCTIONAL CATEGORY : Type II fatty acid biosynthesis pathway 
 InhA, the enoyl-ACP reductase in Mycobacterium tuberculosis is an attractive target for 
the development of novel drugs against tuberculosis, a disease that kills more than two million 
people each year.  
 InhA is the target enzyme of the current first line drug isoniazid for the treatment of 
tuberculosis infections. [18] 
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 Crystal structure of the ternary complex between InhA, NAD(+), and PT70 reveals the 
molecular details of enzyme-inhibitor recognition and supports the hypothesis that slow onset 
inhibition is coupled to ordering of an active site loop, which leads to the closure of the 
substrate-binding pocket.  
        InhA(enoyl-[acyl-carrier-protein]reductase),involved in mycolic acid synthesis is a target of 
front-line anti-tubercular drugs, such as isoniazid and ethionamide.[19]  
BASIC NUCLEUS INFORMATION: 
          Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. In 
many aspects it can be related to well established and very fundamental aromatic molecule, 
benzene, with one C-H group replaced by a nitrogen atom. Pyridine has a conjugated system of 
six π-electrons exactly as benzene has, that are delocalized over the heterocyclic ring.The 
molecule is planar in nature and follows Huckel criteria for aromaticity. 
                                              
N    
 
Fig No 3: Structure of Pyridine Nucleus 
Physically C5H5N Organic base; flammable, toxic yellowish liquid, with penetrating aroma and 
burning taste; soluble in water, alcohol, ether, benzene, and fatty oils; boils at 116 °C(20)  
            Pyridines find omnipresent applications in medicaments and in agrochemicals.  The 
leading group are antimicrobials (isoniazid), and histamine h1 antagonists such as pheniramine , 
but also anticancer, analgesic, and antidepressant agents. 
            Pyridine derivatives continue to attract great interest due to the wide variety of interesting 
biological activities observed for these compounds, such as anticancer, analgesic, antimicrobial, 
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and antidepressant, activities. Pyridine is used in the pharmaceutical industry as a raw material 
for various drugs, vitamins, and fungicides and as a solvent  
 
Pyridine derivatives  have following pharmacological activities: 
1.Anticancer activity[21] 
2.Antiviral activity[22] 
3.Antimicrobial activity.[23] 
4.Analgesic activity[24] 
5.Antichagastic activity[25] 
6.Antifungal activity[26] 
7.Antidiabetic activity[27] 
8.Antibacterial activity[28] 
 
DRUG DISCOVERY: 
 The process of drug discovery is very complex and requires interdisciplinary effort to 
design effective and commercially feasible drugs. Earlier drug discovery has been a trial and 
error process. The process of drug development has evolved with time. New understanding of the 
quantitative relationship between structure and biological activity ushered the beginning of 
computer –aided drug design with the help of computers, a new era has begun in drug discovery. 
The development cost will be cut by almost third. The development times are reduced. [29] 
LEAD AND LEAD OPTIMIZATION: 
 A lead is defined as a compound, usually a small organic molecule that demonstrates 
desired biological activity on a validated molecular target. Lead optimization is technique of 
refining 3D structures of drug molecules and promoting the binding of drug to protein active 
sites.  
          In this technique modification of a structure of the drug molecules is done by docking 
every specific structure of a drug compound in active site of protein and calculating the extent of 
the interaction.[30] Optimization aids in the several modification of newer molecules in order to 
improve the physico-chemical properties and biological activity for a given set of compounds in    
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the library. Further structural modification improves the affinity, reactivity towards target and 
enhances stability during metabolism.[29] 
TYPES OF DRUG DESIGN: 
  Advances in computation techniques and hardware have facilitated the application of in-
silico methods in the discovery process drug design can be categorized as two types 
 Structure based drug design  
 Ligand based drug design 
Structure based drug design: 
 SBDD is the approach where the structural information of the drug target is exploited for 
the development of inhibitors receptor structure(s) is a prerequisite for this method.Most 
commonly the structure of the receptor is determined by experimental techniques such as X-ray 
crystallography or NMR. If the structure of the protein drug target is not available, protein 
structure can be predicted by computational methods threading and homology modelling.  
Ligand based drug design: 
 It is also called indirect drug design. Ligand based drug design is an approach used in the 
absence of the receptor 3D information and it relies on knowledge of molecules to the biological 
target of interest. 3D quantitative structure activity relationship (3D QSAR) and pharmacophore 
modelling are the most important and widely used tools in the ligand based drug design. They 
can provide protective models suitable for lead identification and optimization.[31] 
COMPUTER AIDED DRUG DESIGN  
  Computer aided drug design use as computational chemistry to discover, enhance or 
study drugs and related biologically active molecules. Molecular mechanics or molecular 
dynamics are most often used to predict the confirmation of the small molecule and to model 
conformational changes in the biological target but may occur when the small molecules binds to 
it. 
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 Molecular mechanics methods may also be used to provide semi quantitative prediction 
of the binding affinity also knowledge based scoring function may be used to provide binding 
affinity estimates.[32] 
 Drug design with the help of computers may be used at any of the following stages of 
drug discovery 
 Hit identification using virtual screening (structure or ligand based-based design)  
 Hit-to-lead optimization of affinity and selectivity (structure based design, QSAR, etc)  
 Lead optimization, optimization of other pharmaceutical properties while maintaining 
affinity. 
 In order to overcome the insufficient prediction of binding affinity calculated by resent 
scoring functions, the protein-ligand interaction and compound 3D structure are used to 
analysis[33]  
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AIM AND OBJECTIVE 
 
AIM: 
 To develop the novel and potent anti-tubercular agents against InhA enzyme (Enoyl acyl 
carrier protein reductase) 
OBJECTIVE: 
To design molecules, synthesize, characterize and determine antitubercular activities, 
cytotoxicity and  acute toxicity. 
The plan of work includes: 
 Design of InhA (enoyl-Acyl Carrier Protein  reductase) inhibitors by docking studie 
susing Autodock (1.5.6 version)  software. 
 Insilico Drug likeness prediction. 
 Insilico Toxicity Assessment. 
 Laboratory synthesis of those compounds with top Docking Scores. 
 Characterization of the synthesized compounds by 
 Infrared Spectroscopy. 
 H1 Nuclear Magnetic Resonance Spectroscopy. 
 Melting point. 
 GC-Mass Spectroscopy. 
 LC-Mass Spectroscopy. 
 In-vitro anti -tubercular activity of synthesized compounds (MABA). 
 Acute Toxicity on mice 
 Cytotoxicity on animal kidney cell. 
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PLAN OF WORK 
The present study will be perform on the basis of flow chart given below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Inh-A(ENOYL ACP-REDUCTASE) TARGET FROM MEDICINAL 
CHEMISTRY JOURNALS 
PHARMACOPHORE 
FRAGMENT 
AND 
KNOWLEDGE 
BASED DRUG 
DESIGN 
AUTODOCK/      
ARGUS                 
PDB : 2h9i 
Docking 
CHEMICAL AND 
TOXICITY FILTERS 
DRUG 
LIKINESS 
PRIORITY 
BASES ON 
SYNTHETIC 
FEASIBILITY 
AND CHEMICAL 
AVAILABILITY 
20 HITS OF DIFFERENT 
ANALOGUE 
SYNTHESIS 
PURIFICATION BY RECRYSTALLISATION AND 
COLUMN CHROMATOGRAPHY 
CHARACTERIZATION BY USING IR, NMR, GC-MS, 
LC,MS. 
ANTI-TUBERCULAR ACTIVITY BY MABA 
METHOD,ACUTE TOXICITY,CELL LINE STUDY. 
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LITERATURE REVIEW  
        In order to know the current status regarding the advances in TB the literature pertaining to 
the disease, design, synthesis, characterisation and biological evaluation were reviewed. 
LITERATURE REVIEW FOR TARGET ENZYME: 
1.Banerjee et al., 1994 reported the wild-type inhA gene of M. tuberculosis or M. smegmatis 
was shown to confer INH resistance and ethionamide (ETH) resistance to M. smegmatis and to 
Mycobacterium bovis BCG when transferred on a multicopy .Moreover, a point mutation 
(causing the amino acid substitution S94A) within the inhA genes of an INH-resistant M. 
smegmatis and an INH-resistant M. bovis mutant was shown to be sufficient to transfer INH and 
ETH resistance to M. smegmatis when transferred by allelic exchange within M. smegmatis.[34] 
 
2.Heym et al., 1994., Ristow et al., 1995.,  reported the numerous groups have identified 
mutations from INH-resistant clinical isolates of M. tuberculosis within the promoter of inhA 
and the inhA protein product that are consistent with the premise that inhA encodes the target of 
INH and ETH in M. tuberculosis.[35] 
 
3.Johnsson and Schultz, 1994 the inhA gene was predicted to encode an enoyl-ACP reductase 
of the fatty acid synthase II (FASII) system of mycobacteria. In an in vitro mycolic acid 
synthesis assay, KatGactivated INH inhibited the activity of purified InhA protein.[36] 
 
4.Mdluli et al. (1998)A biochemical approach was used to identify another gene involved in 
INH resistance, kasA, which encodes a b-ketoacyl-ACP synthase This protein was reported to be 
covalently associated with INH and ACP. Using radioactive INH,  the activated INH binds ACP 
in M. tuberculosis cells, but it remains unclear what the chemical nature of this binding is and 
whether it is relevant to INH action.[37] 
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REVIEW OF LITERATURE RELATED TO THE EVALUATION OF ANTI 
TUBERCULAR ACTIVITY BY MABA : 
 
5. Scott G Franzblau. et al. studied MIC determination by MABA. A colorimetric, Microplate 
Based Alamar Blue Assay (MABA) method was used to determine the MICs of Isoniazid, 
Rifampin, Streptomycin and Etambutol for 34 peruvian Mycobacterium tuberculosis isolates and 
the H37Rv strain by using bacterial suspensions prepared directly from media. The MABA is a 
simpe, rapid, low cost, appropriate technology which does not require extensive instrumentation 
and which makes use of a nontoxic, temperature stable reagent [38]. 
 
6. Sephra N Rampresad. et al. studied the various applications of Alamar Blue as an indicator. 
Alamar Blue is a redox indicator that is used to evaluate metabolic function and cellular health. 
The Alamar Blue Bioassay is being utilized to access cell viability and cytotoxicity in a range of 
biological and environmental system and in a number of cell types including bacteria, yeast, 
fungi, and protozoa.[39] 
 
7. Jose de Jesus Alba-Romero et al. applied the Alamar Blue Assay to determine the 
susceptibility to anti-tuberculosis pharmaceuticals.[40] 
LITERATURE FOR TUBERCULOSIS: 
8. Rahul Jain et al. (2005) have shown that Tuberculosis (TB) is one of the most devastating 
diseases primarily due to several decades of neglect, and presents a global health threat of 
escalating proportions. TB is the second leading infectious causes of mortality today behind only 
HIV/AIDS.[41] 
 
9 James C Sacchettini et al. (2004) worked on TB drug discovery. Addressing issues of 
persistence and resistance by reviewing the recent developments of some of the pathways 
involved in a persistent infection and pathogenesis of mycobacterium tuberculosis, which reveal 
new targets for drug development. [42]  
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LITERATURE REVIEW FOR DRUG DESIGN : 
10.Wermuth C G ., (2006) reviewed the similarity in drugs with the importance and reflections 
on analogue design. He also clarified the terminology of analogue design by establishing a clear 
distinction among three kinds of analogues.[43]  
 
11Ghorpade S R et al ., (2013) studied a pharmacophore-based search which led to the 
identification of thiazolopyridine urea as a novel scaffold with antitubercular activity acting 
through inhibition of DNA Gyrase B (GyrB) ATPase. [44] 
 
12. Kore P P et a]., (2012) reported a brief history of CADD, DNA as target, receptor theory, 
structure optimization, structure-based drug design, virtual high-throughput screening (vHTS) 
and graph machines. [45] 
 
 13.Frederick W G et al , (2015) reported the  general principles that should be applied to 
ensure the building block collection’s impact on drug discovery projects.[46] 
 
LITERATURE REVIEW FOR SPECTROSCOPY : 
14.Gurdeep R. Chatwal et al.,(2005) Text book on Instrumental methods of chemical 
analysis.47 
15.P.S.Kalsiet al.,(2007)Text book on Spectroscopy of organic compounds.[48] 
16.D.Kealeyet al.,(2010)Text book on Instant notes Analytical Chemistry.[49] 
17.Y.R.Sharma,et al.,(2008)Text book on Elemental Organic Spectroscopy.[50] 
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LITERATURE REVIEW FOR PYRIDINE: 
18. Xia et al., 2006., reported a  series of novel Schiff base derivatives with different substituent 
were screened for antibacterial activity against S. areus. Synthesized compounds showed a 
significant antibacterial activity [51] 
N
N
H
N
O
OO NH
N
O
 
19. Mohsen et al.,  reported a synthesis of series of sulfapyridine-polyhydroxyalkylidine (or 
arylidene)-imino derivatives (Schiff’s bases) was presented by  having considerable cytotoxic 
effect against breast carcinoma cell lines MCF7 and cervix carcinoma cell line HELA in 
comparison with5-flurouracil and doxorubicin.[52] 
N N
H
S
O
O
N
CH
(CH2)11
 
20.Lee et al synthesized a series of 2-(thienyl-2-yl or - 3-yl)-4-furyl-6-aryl pyridine derivatives 
and evaluated for their topoisomerase I and II inhibition and cytotoxic activity against human 
cancer cell lines. Compounds were showed moderate topoisomerase I and II inhibitory activity 
and showed significant topoisomerase II inhibitory activity. Most significant cytotoxicity against 
Hela, K562, HCT15, and MCF-7 cell lines, was shown by the compound [53] 
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N
O
S
O
CH3
 
21. Fan Zhang et al. (2011), synthesized in vitro anti-tumor activity of 2-amino-3 cyano-6-(1 H 
-indol-3- yl)-4-phenyl pyridine derivative.[54] 
N
CN
NH2
N
 
22. Ulrich Jacquemard et. al. Synthesized 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-
phenyl]-pyridine derivatives as CDK inhibitors and cytotoxic agents. [55] 
 
N
NH
HO
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23. Onnis et al., synthesized and evaluated the anticancer activity of 2 arylamino-6-
trifluoromethyl-3- (hydrazonocarbonyl) pyridines. The potent compound was 2, 6- 
dichlorobenzaldehydehydrazone (11), which inhibited the growth of all tested cancer cell lines 
with nanomolar potency, without having any animal toxicity [56] .  
 
 
24. Cui et al., synthesized a series of substituted piperazinyl pyridyl oxazolidinone compounds 
and evaluated them against Gram positive organism (Staphylococci, Streptococci, 
Enterococci).[57] 
N
NNN O
NHAc
O
H3CO
O
 
LITERATURE REVIEW FOR DESIRED CHEMICAL ENTITIES: 
25.Stanforth et al. have developed a single-step synthesis of alkyl, aryl, heteroatom, and ester 
2,3,6-trisubstituted pyridines in moderate to good yield from amidrazones, a,b-diketoesters, and 
2,5-norbornadiene [58] 
 
NHN
N
H
O
Cl
Cl
F3C
CH3
Cl
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R NH2
N
H2N
+
COO2EtO
RO
Ethanol
Reflex
N
N
N COO2Et
R2R1
NR1 R2
COO2Et
 
 
26.Ellman et al. have developed a single-step, transitionmetal- catalyzed [4+2] method for the 
synthesis of di-, tri-, tetra-, and pentasubstituted pyridines from a,b-unsaturated imines and 
alkynes.[59] 
 
R2
N
R1
R3
Bn
+
R5
R4
Toluene
1000C
N
R2
R3
R1
R4
Bn
R5
N
R1
R2
R3
R4
R5
Toluene
Pd/C
1 atm H2
 
LITERATURE REVIEW FOR SCHIFF BASES: 
27.Ghadage et al. reported some novel Schiff’s bases of 3-{[2-({(E)-[substituted) phenyl] 
methylidene}amino)ethyl]amino}quinoxalin-2(1H)-one  and evaluated for in vivo anticonvulsant 
activity by using pentylene tetrazole-induced seizure model.[60] 
 
N
H
N
H
N
N
R  
R= Cl, NO2, OH, OCH3, N(CH3)2 
 
28. Asiri et al. synthesized a series of 1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-
onecontaining Schiff’s bases  and screened for their antibacterial activities. 1,5-dimethyl-2-
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phenyl-1,2-dihydro-3H-pyrazol-3-one Schiff’s base derivatives were prepared by the reaction of 
4-aminophenazone with different substituted aromatic aldehydes [61].  
 
N
N
O
N
CH3
CH3
H
R
 
R= 2-Cl-C6H4, 2CN-C6H4, 2-OCH3-C6H4, 4-N(CH3)-C6H4 etc. 
 
29. Ghadage et al.  synthesized a novel series of 3-[substituted(phenylmethylidene] 
amino)ethyl)amino] quinoxalin-2(1H)-one ( from [3-(2-aminoethyl)amino]quinoxalin- 2(1H) one 
and aromatic aldehydes. Compounds were screened for in vitro anti-inflammatory activity using 
carrageenan-induced paw model and produced significant inhibition of paw oedema [62].  
 
N
H
N
H
N
N Ar
 
Ar= C6H5, 3-NO2-C6H4, 2-OH-C6H4, 4-OCH3-C6H4, CH=CHCH2C6H5 
 
30. Hutchinson et al.  synthesized fluorinated analogues of 2-(4-aminophenyl) benzothiazoles 
among which 2-(4-amino-3-methylphesnyl)-5-fluorobenzothiazole exhibited selective and potent 
anticancer activity.[63] 
N
S
N
R
 
R= Cl, Br, F etc. 
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31. Rapolu et al. reported synthesis of a series of Schiff bases 2-methyl -1-H indole-3-
carbohydrazide and  N-benzylidine-2-methyl-1-Hindole-3-carbohydrazide as anti-inflammatory 
agents.[64] 
 
N
NH
H
N
H
C
Ar
 
 
32. Ronad et al.  prepared a series of 7-(2-substituted phenylthiazolidinyl)-benzopyran-2-one de 
rivatives of Schiff bases , and evaluated for anti-bacterial and anti-fungal activities against 
various bacterial and fungal Anand et al : Schiff bases: A Review on Biological Insights 865 
strains.[65] 
O ON
CH3
R  
 
From the literature review the following points are concluded 
 TB is the deadliest disease across the world wide which has to be treated. 
 Inh A (enoyl ACP- Reductase) is the most attractive target enzyme to treat 
Mycobacterium tuberculosis. 
 It is clear that pyridine scaffold has a tremendous activity against the Mycobacterium 
tuberculosis from the literature review. 
  
MATERIALS AND METHODS 
 
Department of Pharmaceutical Chemistry, COP, MMC, Chennai-03 Page 22 
 
MATERIALS AND METHODS 
 
COMPUTER AIDED DRUG DESIGN : 
            A binding interaction between a small molecule ligand and an enzyme protein results in 
activation or inhibition of the enzyme, which results in agonism or antagonism. Identification of 
new ligands for a given receptor by searching largedatabases of 3D structures of small molecules 
to find those fitting the binding pocket of the receptor using docking programs. This method is 
known as virtual screening.[66] 
DOCKING: 
            Docking program is used to fit the ligand molecule into the target structure in a variety of 
position, conformations and orientations. Docking mode is known as pose. Each pose scored 
based on its complementarities to the target in terms of shape and properties such as 
electrostatics in order to identify the most favorable energetic pose. 
SCORING FUNCTIONS[67]: 
           One early general-purposed empirical scoring function to describe the binding energy of 
ligands to receptors was developed by Böhm. This empirical scoring function took the form: 
ΔG0 – empirically derived that in part corresponds to the overall loss of translational and 
rotational entropy of the ligand upon binding. 
      ΔGhb – contribution from hydrogen bonding 
      ΔGionic – contribution from ionic interactions 
ΔGlip – contribution from lipophilic interactions where is surface area of lipophilic contact 
between the ligand and receptor 
ΔGrot – entropy penalty due to freezing a rotatable bond in the ligand bond upon binding 
ΔGbind = -RT ln Kd 
 
Kd = 
[𝐋𝐢𝐠𝐚𝐧𝐝] [𝐑𝐞𝐜𝐞𝐩𝐭𝐨𝐫]
[𝐂𝐨𝐦𝐩𝐥𝐞𝐱]
 
 
ΔGbind = ΔG desolvation + ΔG motion + ΔG configuration + ΔG interaction 
Where: 
ΔG desolvation is the enthalpic penalty for removing the ligand from solvent 
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ΔG motion is the entropic penalty for reducing the degrees of freedom when a ligand binds to its 
receptor 
ΔG configuration is the conformational strain energy required to put the ligand in its "active" 
conformation 
ΔG interaction is the enthalpic gain for "resolvating" the ligand with its receptor. 
According to Gibbs free energy equation, the relation between dissociation equilibrium constant, 
Kd, and the components of free energy was built. 
 
MOLECULAR DOCKING BY AUTODOCK®: 
       Autodock® 4.2.5.1 is an automated procedure for predicting the interaction of ligands with 
biomacromolecular targets. Progress in biomolecular x-ray crystallography continues to provide 
important protein and nucleic acid structures. These structures could be targets for bioactive 
agents in the control of animal and plant diseases, or simply key to the understanding of 
fundamental aspects ofbiology. The precise interaction of such agents or candidate molecules 
with their targets is important in the drug discovery process. 
          In any docking scheme, two conflicting requirements must be balanced: the desire for a 
robust and accurate procedure, and the desire to keep the computational demands at a reasonable 
level. The ideal procedure would find the global minimum in the interaction energy between the 
substrate and the target protein and exploring all available degrees of freedom (DOF) for the 
system. 
          AutoDock® combines two methods to achieve these goals: rapid grid-based energy 
evaluation and efficient search of torsional freedom. The current version of AutoDock® using 
the Lamarckian Genetic Algorithm and empirical free energy scoring function, typically will 
provide reproducible docking results for ligands with approximately 10 flexible bonds. The 
quality of any docking results depends on the starting structure of both the protein and the 
potential ligand. The protein and ligand structure need to be prepared to achieve the best docking 
results. 
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 Protein preparation 
  Ligand preparation 
  Receptor grid generation 
  Ligand docking (screening)  
 
DOCKING PROCEDURE 
Preparation of protein: 
 
 
 Read molecule from the file (allows reading of PDB coordinate files.) 
 Edit -Charges – Compute Gasteiger (for arbitrary molecules) 
 Edit – Hydrogen –Merge non polar 
 Save as .pdb in AutoDock® folder 
 
Preparation of Ligand:  
 
 Docking – docking parameters: opens a panel for setting the parameters used 
during the docking calculation, including options for the random number 
generator, options for the force field, step sizes taken when generating new 
conformations, and output options. 
 Ligand –Input from file 
 Ligand – Torsion –choose torsion: Rotatable bonds are shown in green, and non- 
rotatable bonds are shown in red. Bonds that are potentially rotatable but treated 
as rigid, such as amide bonds and bonds that are made rigid by the user, are 
shown in magenta. 
 Ligand – Torsion –set number of torsion: sets the number of rotatable bonds in 
the ligand by leaving the specified number of bonds as rotatable. 
 Ligand – Output – save as .pdbqt in AutoDock folder  
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Preparation of Docking Parameters: 
 
 Docking –Open the macromolecules – set rigid file name. 
 Docking – ligand – open the ligand. 
 Docking –search parameters – genetic algorithm parameters : this command 
opens a panel for setting the parameters used by each of the search algorithms, 
such as temperature schedules in simulated annealing and mutation/crossover 
rates in genetic algorithms. 
 Docking- output –Lamarkian GA –save as .dpf (docking parameterfile) Open 
command prompt [autodock4.exe –p a.dpf –l a.dlg]  
 
Visualization / Interpretation of Docking: 
 Analysis –Docking – open .dlg (docking log file) file 
 Analysis – open the macromolecule 
 Analysis – Confirmation –Play and Play ranked by energy : Play- will use the 
order of conformations as they were found in the docking calculations, and Play 
Ranked By Energy will order the conformations from lowest energy to highest 
energy. 
 Analysis – Load : Information on the predicted interaction energy is shown at the 
top and the individual conformations 
 Analysis – Docking – show interaction: specialized visualization to highlight 
interactions between the docked conformation of the ligand and the receptor. 
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LIPINSKI’S RULE[68] 
        Variants 
In an attempt to improve the predictions of druglikeness, the rules have spawned 
many extensions,  
1. Partition coefficient log P in −0.4 to +5.6 range 
2. Molar refractivity from 40 to 130 
3. Molecular weight from 180 to 500 
4. Number of atoms from 20 to 70 (includes H-bond donors [e.g. OHs and NHs] and 
H-bond acceptors [e.g. Ns and Os]) 
Also the 500 molecular weight cutoff has been questioned. Polar surface area 
and the number of rotatable bonds has been found to better discriminate between 
compounds that are orally active and those that are not for a large data set of compounds 
in the rat. 
 In particular, compounds which meet only the two criteria of: 
1. 10 or fewer rotatable bonds and 
2. Polar surface area no greater than 140 A2 
are predicted to have good oral bioavailability. 
 IN-SILICO TOXICITY PREDICTION OSIRIS® : 
            In silico toxicity prediction is done using OSIRIS® Property Explorer. It is a free 
software available for access in the Organic Chemistry Portal. Using this prediction tool, 
mutagenicity, tumerogenicity, skin irritation and reproductive effects can be calculated. The 
prediction properties relies on a precompiled set of structure fragment that gives rises to toxicity 
alerts in case they are encountered in the structure currently drawn. These fragment lists is 
created by rigorously shredding all compounds in the data base known to be active in a certain 
toxicity class. During the shredding any molecule is first cut at every rotatable bonds leading to a 
set of core fragments. 
MOLINSPIRATION® : 
            The designed and docked molecules are screened in silico using MOLINSPIRATION® 
Cheminformatics software to evaluate drug likeness. This tool is quick and easy to use. It is a 
software available online for calculation of important molecular properties log P, polar surface 
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area, number of hydrogen bond donors and acceptors and others, as well as prediction of 
bioavailability score for the most important drug targets (GPCR ligands, Kinase inhibitors, ion 
channel modulators, nuclear receptors). 
HETEROCYCLIC CHEMISTRY: 
         In the area of new drug development heterocyclic derivatives are evaluated for their various 
biological actions.  Heterocyclic derivatives are found to have significant pharmacological 
activities. Among various compounds I have chosen Pyridine a six membered ring containing 
nitrogen at position 1. 
PYRIDINE NUCLEUS: 
2
N
1
6
5
4
3
 
 
SYNTHETIC SCHEME:- 
 Synthesis of Schiff base: 
N
NH2
+
O
N
N
Aromatic aldehyde
4-6 hours/Reflex
Ethanol
CH3COOH
Substituted Schiff 
base .
R
R
Amine
R
R
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Procedure: 
An equimolar quantity of 3,5-dichloro 4-amino pyridine [0.01mole] was added to various 
Aldehydes [0.01mole] and dissolved in absolute ethanol, few drops of glacial acetic acid was 
added as a catalyst, the reaction mixture was reflexed for 4-6 hours on completion of the reaction 
was monitored by TLC, cooled to room temperature and the reaction mixture was poured into 
crushed ice, the product was formed, filterd, dried and recrystallised using ethanol. 
Amines used: 
 3,5-dichloro 4-amino pyridine 
 2-amino 4-methyl pyridine. 
Aldehydes used: 
 3-nitro benzaldehyde 
 4-chloro benzaldehyde 
 Parahydroxy benzaldehyde 
 Indole 3-carbaldehyde 
Mechanism : 
          The formation of a Schiff base from an aldehydes or ketones is a reversible reaction 
and generally takes place under acid or base catalysis, or upon heating. 
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R C
O
R + R-NH2
R C
OH
NHR
R
Aldehyde or
ketone
Primary 
Amine Carbinolamine
N-Substituted imine
R C
NR
R + H2O
 
      The mechanism of Schiff base formation is based on the  neucleophilic addition to the 
carbonyl group. In this case, the neucleophile is the amine. In the first part of the mechanism, 
the amine reacts with the aldehyde or ketone to give an unstable addition compound called 
carbinolamine.The carbinolamine loses water by either acid or base catalyzed pathways. 
Since the carbinolamine is an alcohol, it undergoes acid catalyzed dehydration. 
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N
OH
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H
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R2
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C N R1
H
R
R
+ H2O
C N R1
R
R
H3O+
H+
(Acid-catalysed dehydration)
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REACTANT PROFILE 
1.3,5-DICHLORO 4-AMINO PYRIDINE: 
NH2N
Cl
Cl  
Synonym: 3,5-dichloro 4-pyridinamine 
Molecular Formula: C5H4Cl2N2 
Formula weight: 163 
Melting point:1590C 
Boiling point: 
Solubility : Chloroform , DMSO, Methanol. 
2. 2-AMINO 4-METHYL PYRIDINE: 
N
H3C NH2  
Synonym                     : 4-methyl 2-pyridinamine 
Molecular Formula    : C6H8N2 
Formula weight          : 108.14 
Melting point              : 97-101°C 
Boiling point               : 2310C 
Solubility                     : Soluble in water, chloroform, ethyl acetate. 
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3. P-HYDROXYBEZALDEHYDE: 
O
OH
 
Synonym                    :4-Hydroxy benzaldehyde 
Molecular Formula  : C7H6O2 
Formula weight        : 122.12 
Melting point            : 112-1160C 
Boiling point             :1910C 
Solubility                   : soluble in alcohol and water 
     4. 4-CHLOROBENZALDEHYDE: 
O
Cl
 
Synonym                  : Parachlorobenzene carboxaldehyde 
Molecular Formula : C7H5ClO 
Formula weight       : 140.57 
Melting point           : 460C 
Boiling point            : 213-2160C 
 Solubility                : very slightly soluble in alcohol. 
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4. 3-NITROBENZALDEHYDE: 
O
N+
O
-O
 
Synonym                       : meta-benzaldehyde  
Molecular Formula      : C7H5NO3 
Formula weight            : 151.12g/ mol-1 
Melting point                 : 58.5 0C 
Boiling point                  : 164 0C 
 Solubility                      : Soluble in water 
CHARACTERIZATION 
The purity of the synthesized compounds checked by TLC method and sharp melting point. 
PHYSICAL EVALUATION: 
1. The physical properties of the synthesized compounds are evaluated as follows 
 Colour 
 Nature 
 Solubility 
 Molecular weight 
 Molecular formula 
 Melting point 
 Boiling point. 
2. Moreover the synthesized compounds are characterized by the following instrumental 
methods. 
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IR SPECTROMETRY 
    Infrared spectroscopy is one of most commonly used spectroscopic technique  for 
identification of functional groups  in molecules. IR spectroscopy is an important tool in the 
structural elucidation of organic compounds. In IR spectroscopy finger print region is used to 
compare the two compounds. Infrared  spectrum shows percent transmittance versus 
frequency expressed as wave numbers.(69) 
1. 3540-3300 cm-1 N-H Stretching Vibration  
2. 3670-3230 cm-1 O-H Stretching Vibration  
3. 1690-1630 cm-1 C=N Stretching Vibration  
4. 2975-2840 cm-1 C-H Aliphatic Stretching Vibration  
NMR SPECTROSCOPY 
            Nuclear Magnetic Resonance (NMR) spectroscopy is an important analytical technique 
used in the structural elucidation of organic molecules. It involves the interaction of the 
electromagnetic radiation and the proton of an nucleus of an atom when placed in an externally 
applied static magnetic field. NMR spectra provide the detailed information about a molecule’s 
structure. The chemical shift is used to predict the number of protons with refers to DMSO as 
standard .The NMR spectra is recorded on 300 MHZ BRUKER advance III NMR spectrometer. 
DMSO is used as a solvent. 
1. Aromatic and hetero aromatic compounds 6-8.5 δ  
2. Alcoholic hydroxyl protons 1-5.5 δ  
3. Aldehyde protons 9-10 δ 
 
 HYPHENATED TECHNIQUE: 
GC-MS: 
            Gas chromatography-mass spectrometry is a hyphenated technique, comprised of two 
analytical procedure in sequence, namely a gas chromatography (GC) which perform separation 
process and Mass spectroscopy (MS) which perform detection of separated fragments. 
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LC-MS: 
           LC-MS is a hyphenated technique, combining separation power of HPLC with the 
detection power of Mass Spectrometry. 
BIOLOGICAL EVALUATION 
 Anti-tubercular Activity: 
          There are various assay methods available for the evaluation of  new chemical entities 
against tuberculosis. They are as follows: 
 MicroplateAlamar Blue Assay  
 BACTEC Assay  
 Luciferous Reporter Phage assay  
 Resazurin Micro plate Assay(REMA) 
 Broth Micro Dilution Assay  
 Middle brook(7H 9,7H 10,7H 11) Agar Dilution Assay. 
 Nitrate Reductase Assay 
MICROPLATE ALAMAR BLUE ASSAY (MABA)(70) 
 The anti-microbial activities of the synthesized compounds is determined by 
MABA method. The organism used in the studies is Mycobacteria tuberculosis 
(Vaccine strain, H37 RV strain): ATCC No- 27294.  
 Alamar blue dye is used as an indicator for the determination of viable cells. 
      
 Principle: 
     MABA is an indirect colorimetric method for determining the MICs of TB drugs for 
strains of mycobacterium tuberculosis. In this assay, the redox indicator Alamar blue monitors 
the reducing environment of the living cells. It turns from blue to pink in the presence of 
mycobacterium growth. 
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Procedure: 
1) The anti-mycobacterial activity of the compounds are to be assessed against M. 
tuberculosis using microplateAlamar blue assay (MABA). 
2) This methodology is non- toxic, uses a thermally stable reagent and shows good 
correlation with proportional and BACTEC radiometric method. 
3) Briefly, 200 ml of sterile deionized water is added to all outer perimeter wells of sterile 
96 wells plate to minimize evaporation of medium in the test wells during incubation. 
4) The 96 wells plate received 100µl of the Middle brook 7H9 broth and serial dilution of 
compounds are placed directly on plate. 
5) The final drug concentrations tested is made up to 100 to 0.2µg/ml. 
6) Plates are covered and sealed with Para film and incubated at37oC for five days. 
7) After this time, 25µl of freshly prepared 1:1 mixture of Alamar Blue reagent and 10% 
Tween 80 was added to the plate and incubated for 24hrs. 
8) A blue colour in the well is interpreted as no bacterial growth, and pink colour was 
scored as growth. 
The MIC is defined as lowest drug concentration which prevents the colour change from blue to 
pink  
 
ACUTE TOXICITY: 
ACUTE ORAL TOXICITY STUDY: 
Acute oral toxicity study (Limit Test) was designed as per the OECD guidelines (423). 
Principles and purpose 
        The main purpose of acute toxicity is to evaluate the degree of toxicity in a quantitative and 
qualitative manner. 
Experimental Animals 
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        Six healthy adult Albino mice were weighing between 20-25g were selected for the study. 
For all the six animals food, but not water was withheld overnight prior to dosing. 
Selection of dose levels and administration of dose: 
        Being synthetic molecules, the mortality was unlikely at the highest starting dose level 
(2000mg/kg/b.w). Hence a limit test one dose levels of 2000mg/kg/b.w was conducted in all 
animals as per the OECD guidelines (423). 
Procedure: 
Animals are observed individually after dosing at least once during the first 30 minutes, 
periodically during the first 24 hours, with special attention given during the first 4 hours, and 
daily thereafter, for a total of 14 days, except where they need to be removed from the study and 
humanely killed for animal welfare reasons or are found dead. However, the duration of 
observation should not be fixed rigidly. It should be determined by the toxic reactions, time of 
onset and length of recovery period, and may thus be extended when considered necessary. The 
times at which signs of toxicity appear and disappear are important, especially if there is a 
tendency for toxic signs to be delayed. All observations are systematically recorded with 
individual records being maintained for each animal. 
CYTOTOXICITY(71) 
MATERIAL: 
Cell line: Vero (African green monkey kidney cells), from NCCS Pune, India. 
DMEM, Fetal Bovine Serum (FBS), antibiotic–antimicotic solution from Thermoscientifc and 
SRB reagent from sigma Aldrich, USA. Tissue culture flasks, 96, well micro culture plates from 
Eppendorf, Germany. 
METHODS: 
Maintenance of cell lines 
     Vero (African green monkey kidney cells), cell line procured from NCCS Pune, India, 
procured from NCCS Pune were grown in 25 cm2 tissue culture flasks containing DMEM 
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medium supplemented with 10% FBS, 1% L- glutamine and 1% antibiotic-antimicotic solutions 
at 37ºC in CO2 incubator in an atmosphere of humidified 5% CO2 and 95% air. The cells were 
maintained by routine sub culturing in 25 cm2 tissue culture flasks.(71) 
Sub culturing process of cell lines 
 The culture media from the flasks containing monolayer culture was aspirated and 
washed with sterile phosphate buffered saline (PBS). 
 To the flasks, 1 ml of 0.2% trypsin-EDTA solution was added and after few seconds it 
was aspirated and flask was kept in incubator 2-3 min. for detachment. 
 The flasks were removed from the incubator and gently tapped to detach all the adhering 
cells. The cell detachment was confirmed by observing under an inverted microscope 
(Nikon Eclipse TE 2000-5, Japan). 
 Once the cells were completely detached from the flasks, 2-3 ml of DMEM media 
containing 10% FBS was added and mixed well. 
 From the stock cell suspension, 1 x 105 viable cells/ml suspended in media were seeded 
in 25cm2 tissue culture flask containing about 4ml of fresh media and incubated until the 
flasks attained 60-70% confluence. 
Trypsinization 
To obtain a single cell suspension from a monolayer culture, cells were dislodged form the 
culture flasks by trypsinization. 
 From a 60-70% confluent flask, the culture media was aspirated out using a micropipette. 
 Cells were washed with 3 ml of PBS to remove trace amount of media. 
 To each culture flask 1 ml of trypsin-EDTA was added and after few seconds it was 
aspirated and the flask was kept in the incubator for 3-4 min for cell detachment 
 Culture flasks were observed under an inverted microscope (Nikon Eclipse, Japan) to 
ensure that cells were completely dislodged. 
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 Trypsin activity was stopped by adding 2-3ml media containing 10% FBS. 
Seeding: 
Exponentially growing cell lines were harvested from 25cm2 Tissue culture flask and a stock cell 
suspension (5X106 cell/ml) was prepared. 
 A 96-well flat bottom tissue culture plate was seeded with 5 x103 cells in 0.1 ml of 
DMEM medium supplemented with 10% FBS and allowed to attach for 24hrs. 
Preparation of drug dilutions: (serial dilution) 
 50mg/ml stock solution was prepared using 100% DMSO solution. From this stock 
solution various final concentrations (viz. 62.5, 125, 250 and 500 µg/ml) of test 
compound solution was prepared as follows: 
 500 µg/ml: 10 µL sol. was taken from stock and to this 990 µl media was added. 
 250 µg/ml: From 500 µg/ml 500 µl was taken and diluted with 500 µl with media. 
 125 µg/ml: From 250 µg/ml 500 µl was taken and diluted with 500 µl with media. 
 62.5 µg/ml: From 125 µg/ml 500 µl was taken and diluted with 500 µl with media 
 After 24 hrs of incubation, cells were treated with 100 µl of test solutions from respective 
above stocks and the cells were incubated for 48 hrs. 
 The cells in the control group received only the medium containing the 0.5, 0.1 % 
DMSO. 
 Each treatment was performed in triplicates. 
SRB Assay: 
Principle: 
Sulforhodamine B (SRB) assay was developed in 1990 is one of the most widely used methods 
for in vitro cytotoxicity screening. The assay relies on the ability of SRB to bind to protein 
components of cells that have been fixed to tissue-culture plates by trichloroacetic acid (TCA). 
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SRB is a bright-pink amino xanthene dye with two sulfonic groups that binds to basic amino-
acid residues under mild acidic conditions and dissociate under basic conditions. As the binding 
of SRB is stoichiometric, the amount of dye extracted from stained cells is directly proportional 
to the cell mass. 
Reagents 
 10% (wt/vol) TCA 
 1% (vol/vol) acetic acid 
  0.057% (wt/vol) SRB (Sigma, cat. no. 86183) in 1% (vol/vol) acetic acid 
 10 mM unbuffered Tris base solution 
Cell fixation and staining 
 100 μl ice cold 10% (wt/vol) TCA was gently added to each well and the plates at 4 °C 
for 1 h. 
 The plates were washed four times under slow-running tap water and excess water was 
removed by air drying the plates at room temperature. 
 100 μl 0.057% (W/V) SRB was added to the wells and incubated for 30 minutes at room 
temperature in dark. 
 The plates were then washed with 1% acetic acid to remove the unbound dye. The plates 
were air dried at room temperature. 
 200 μl of Tris base (10mM) was added to the wells and plates were places on shaker for 
10 min. 
 Optical density was read at 540 nm in a ELISA plate reader. Percentage cell death was 
calculated (absorbance of control wells- absorbance of test wells / absorbance of control 
wells) x 100. 
IC50 was calculated from the % cell death using GraphPad Prism 7 software. 
RESULT AND DISCUSSION 
 
Department of Pharmaceutical Chemistry, COP, MMC, Chennai-03 Page 41 
 
RESULTS AND DISCUSSION 
 
RESULT AND DISCUSSION: 
PREDICTION OF DRUG LIKENESS: 
            The designed and docked molecules were screened insilico using Molinspiration 
cheminformatics® to evaluate drug likeness. Molinspiration® is used to calculate important 
physicochemical properties of molecules such as log P, polar surface area, number of hydrogen 
bond donors and acceptors.  
 Variants:        
           In an attempt to improve the predictions of druglikeness, the rules have spawned many 
extensions, for example the following:  
 Partition coefficient log P in −0.4 to +5.6 range 
 Molar refractivity from 40 to 130180 
 Molecular weight from to 500 
 Number of atoms from 20 to 70 (includes H-bond donors [e.g. OHs and NHs] and H-bond 
acceptors      
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PREDICTION OF DRUG LIKENESS: 
The snapshot of the molecules in drug likeness is presented below for the chosen compounds. All 
the compounds were compare with Lipinski’s rule and chosen for synthesis.   
COMPOUND NAME: DCP1 
 
 
 
 
 
 
 
 
COMPOUND NAME: DCP2 
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 COMPOUND NAME: DCP3 
 
 
 
 
 
 
 
 
COMPOUND NAME: PIA 
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DOCKING STUDIES: 
ACTIVITY PREDICTION: 
      More than 200 scaffolds were docked against the MTB enzyme Inh A (Enolyl Acyl Carrier 
Protein) (2h9i) by using Autodock® 4.2.5.1 software. The result of the docking and the view for 
different compound is presented below. 
 
Table 1: Docking Score And View Using Autodock® 4.2.5.1 
Compound 
code 
Structure Docking 
Score 
Docking view 
 
 
 
DCP1 
 
 
N
Cl Cl
N
NO2  
 
-5.58 
Kcal/mol 
 
 
 
 
DCP2 
 
 
N
Cl Cl
N
Cl  
 
 
-7.02 
Kcal/mol 
 
 
RESULT AND DISCUSSION 
 
Department of Pharmaceutical Chemistry, COP, MMC, Chennai-03 Page 45 
 
 
DCP3 
 
 
N
N
Cl Cl
OH
 
 
 
-6.53 
Kcal/mol 
 
 
 
PIA 
 
 
N N
N
CH3
 
 
 
-7.0 
Kcal/mol 
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Table 2 : 2h9i Interaction With Ligand 
Compound     
code 
 
 
Interaction with Aminoacid 
 
Hydrogen bond Interaction 
 
 
 
 
DCP1 
 
 
 
 
 
 
 
 
DCP2 
 
 
 
 
 
 
DCP3 
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PIA 
 
 
 
 
 
 
 
 
 
 
 
 
Toxicity prediction: 
 OSIRIS® Property Explorer the online software of Thomas Sander, Actelion 
Pharmaceuticals Ltd., Gewerbestrasse 16, and 4123 Allschwil, Switzerland. This applet predicts 
physico-chemical properties and detects potential toxicity risks for any drawn chemical structure 
in real time.  
          
           The Prediction result was indicated by color coded. For predicting properties of a 
chemical compound just draw its structure and Property Explorer will start calculating properties 
as soon as a chemical structure is valid. Charges should be balanced and atom valances not 
exceeded. Properties with high risks of undesired effects like mutagenicity or a poor intestinal 
absorption  are  shown in red. Whereas green  color indicates the  drug conform behaviour. 
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Table 3 : Prediction Of Toxicity Using Osiris® Property Explorer 
TOXICITY COMPOUND CODE 
DCP1 DCP2 DCP3 PIA 
MUTAGENIC _ _ _ _ _ _ _ _ _ _ _ _ 
TUMOROGENIC _ _ _ _ _ _ _ _ _ _ _ _ 
IRRITANT _ _ _ _ _ _ _ _ _ _ _ _ 
REPRODUCTIVE 
EFFECT 
_ _ _ _ _ _ _ _ _ _ _ _ 
 
 SAMPLE  CODE :DCP1 
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SAMPLE  CODE :DCP2 
 
SAMPLE  CODE :DCP3 
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SAMPLE CODE: PIA 
 
RESULTS OF SYNTHETIC EFFORTS: 
    The selected 4 compounds were synthesized and recrystallised. Then the synthesized 
compounds were evaluated for their purity through melting point determination and TLC was 
carried out for the determination of absence of present compounds on other new compounds. 
1. 3,5-dichloro 4-amino pyridine 
2. 2-amino 4-methyl pyridine 
TABLE:4 RESULTS OF SYNTHETIC EFFORTS: 
S.NO Compound 
code 
Molecular 
weight 
Percentage 
Yield 
Melting 
point 
 
1 DCP1 295.06 g/mole 76% 780 C 
2 DCP2 286.88 g/mole 78% 1140 C 
3 DCP3 266.91 g/mole 62% 1040 C 
4 PIA 237.55 g/mole 67% 1200 C 
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        The Rf value of the synthesized compounds are distinguished  from the Rf value of the 
reactants. Hence it is concluded that the reaction was completed.  
       The synthesized compounds were subjected to purification by recrystallization and TLC. 
The melting point of the synthesized compounds was founded. The characterization was carried 
out using sophisticated instruments like IR, NMR, and Mass spectroscopy and characteristic 
properties through the aid of computer software. 
Infrared Absorption Spectroscopy: 
         The IR spectrums of the synthesized compounds were inspected for presence of the new 
functional group and absence of the functional group which induced the changes in the chemical 
reaction. 
H1 NMR Spectroscopy: 
        Proton NMR spectroscopy help us  to study the number of equivalent protons and their 
environment thereby we can ascertain the structure of molecule. The positions of the signals help 
us to know the nature of protons viz, aromatic, heteroaromatic, aliphatic, vinyl C-H groups.The 
H1 NMR spectral data of all the synthesized compounds are in conformity with the structure 
assigned. A singlet at 11.02-11.35 was observed for all compounds confirming the presence of 
N-H proton. All the compounds shows the multiplet and doublet signals for the presence of 
aromatic protons between (6.2-7.4)heteroaromatic protons between (7.2-7.8) δppm. 
 
Table no:5 Molecular Weight of Synthesized compounds: 
 
NAME OF 
COMPOUNDS 
 
 
CALCULATED MASS 
 
ACTUAL MASS 
 
               DCP1 295.06g/mole 296.11g/mole 
DCP2 286.88g/mole 285.55g/mole 
DCP3 266.91g/mole 267.11g/mole 
PIA 237.55g/mole 235.28g/mole 
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PRODUCT PROFILE: 
CODE: DCP1 
IUPACNAME: (E)-N-(3,5-dichloropyridin-4-yl)-1-(3 
nitrophenyl)methanimine 
 
N
Cl Cl
N
NO2 
Molecular Formula  = C12H7Cl2N3O2 
Formula Weight  = 296.10888 
Composition              = C(48.67%) H(2.38%) Cl(23.95%) N(14.19%)   
O(10.81%) 
Molar Refractivity  = 73.71 ± 0.5 cm3 
Molar Volume             = 202.2 ± 7.0 cm3 
Parachor               = 550.7 ± 8.0 cm3 
Index of Refraction  = 1.649 ± 0.05 
Surface Tension  = 55.0 ± 7.0 dyne/cm 
Density              = 1.46 ± 0.1 g/cm3 
Polarizability              = 29.22 ± 0.5 10-24cm3 
Monoisotopic Mass  = 294.991532 Da 
Nominal Mass             = 295 Da 
Average Mass              = 296.1089 Da 
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IR SPECTRUM DCP1: 
 
  Table No6: INTERPRETATION OF IR 
S.No Wave number (cm-1) Functional group 
 
1. 
2. 
3. 
4 
 
2929.87 
732.90 
1629.09 
1504.37 
 
C-H Stretching 
C-Cl Stretching 
C=N Stretching 
-NO Streching 
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LC-MS CHROMATOGRAM: DCP1 
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LC-MS SPECTRUM: DCP1 
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NMR SPECTRUM: DCP1 
 
Table No 7: INTERPRETATION OF NMR 
S.No 
 
δ VALUE 
(PPM) 
NATURE OF 
PEAK 
NUMBER OF 
PROTONS 
 
1 
 
2 
 
3 
 
 
 
δ6.8 
 
δ7.9 
 
δ10.2 
 
 
 
Multiplet  
 
Multiplet 
 
Singlet 
 
 
 
5 Protons 
 
5 Protons 
 
1 Protons 
 
 
 
RESULT AND DISCUSSION 
 
Department of Pharmaceutical Chemistry, COP, MMC, Chennai-03 Page 57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRODUCT PROFILE: 
CODE:DCP2 
IUPAC NAME: (E)-1-(4-chlorophenyl)-N-(3,5-dichloropyridin-4 
yl)methanimine 
 
N
Cl Cl
N
Cl  
Molecular Formula  = C12H7Cl3N2 
Formula Weight  = 285.55638 
Composition              =  C(50.47%) H(2.47%) Cl(37.25%) N(9.81%) 
Molar Refractivity  = 72.65 ± 0.5 cm3 
Molar Volume            = 206.1 ± 7.0 cm3 
Parachor              = 534.1 ± 8.0 cm3 
Index of Refraction  = 1.622 ± 0.05 
Surface Tension  = 45.0 ± 7.0 dyne/cm 
Density               = 1.38 ± 0.1 g/cm3 
Polarizability             = 28.80 ± 0.5 10-24cm3 
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IR SPECTRUM DCP2: 
 
Table No:8 INTERPRETATION OF IR: 
S.No Wave number (cm-1) Functional groups 
 
1. 
 
2. 
 
3. 
 
732.90 
 
1550.65 
 
3240.17 
 
C-Cl Stretching 
 
C=N Stretching 
 
C-H Stretching 
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LC-MS CHROMATOGRAM:DCP2 
 
LC-MS SPECTRUM DCP2: 
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NMR SPECTRUM DCP2: 
 
Table No:9 INTERPRETATION OF NMR: 
S.No 
 
δ VALUE 
(PPM) 
NATURE OF 
PEAK 
NUMBER OF 
PROTONS 
 
1 
 
2 
 
 
 
δ6.8 
 
δ8.2 
 
Doublet 
 
Doublet 
 
 
 
 
2 Protons 
 
2 Protons 
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CODE :DCP3 
IUPAC NAME 
4-{(E)-[(3,5-dichloropyridin-4-yl)imino]methyl}phenol 
 
N
N
OH
ClCl
 
 
Molecular Formula  = C12H8Cl2N2O 
Formula Weight  = 267.11072 
Composition              =  C(53.96%) H(3.02%) Cl(26.55%) N(10.49%) O(5.99%) 
Molar Refractivity  = 68.91 ± 0.5 cm3 
Molar Volume  = 194.1 ± 7.0 cm3 
Parachor              = 510.9 ± 8.0 cm3 
Index of Refraction  = 1.628 ± 0.05 
Surface Tension  = 48.0 ± 7.0 dyne/cm 
Density              = 1.37 ± 0.1 g/cm3 
Dielectric Constant  = Not available 
Polarizability              = 27.31 ± 0.5 10-24cm3 
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IR SPECTRUM DCP3: 
 
Table No:10 INTERPRETATION OF IR: 
S.No Wave number (cm-1) Functional groups 
 
1 
2 
3 
4 
 
 
3448.47 
1172.63 
1550.65 
732.90 
 
-OH Stretching 
-C-O Stretching 
 -C=N Stretching 
-C-Cl Stretching 
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LC-MS CHROMATOGRAM DCP3: 
 
LC-MS SPECTRUM DCP3: 
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NMR:DCP3 
 
Table No:11 INTERPRETATION OF NMR: 
S.No 
 
δ VALUE 
(PPM) 
NATURE OF 
PEAK 
NUMBER OF 
PROTONS 
 
1. 
 
2. 
 
δ6.8 
 
δ8.2 
 
Doublet 
 
Doublet 
  
 
 
 
2 Protons 
 
2 Protons 
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PRODUCT DETAILS 
CODE:PIA 
IUPAC NAME: (Z)-N-(1H-indol-3-yl)-1-(4-methylpyridin-2-yl)methanimine 
 
NH
N
N
CH3
 
 
Molecular Formula  = C15H13N3 
Formula Weight  = 235.28382 
Composition               =  C(76.57%) H(5.57%) N(17.86%) 
Molar Refractivity  = 73.00 ± 0.5 cm3 
Molar Volume             = 201.8 ± 7.0 cm3 
Parachor               = 520.8 ± 8.0 cm3 
Index of Refraction  = 1.643 ± 0.05 
Surface Tension  = 44.3 ± 7.0 dyne/cm 
Density               = 1.16 ± 0.1 g/cm3 
Dielectric Constant  = Not available 
Polarizability               = 28.94 ± 0.5 10-24cm3 
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IR SPECTRUM: PIA 
 
Table No:12 INTERPRETATION OF IR 
S.No Wave number (cm-1) Functional groups 
 
1 
2 
3 
 
 
 
3448.47 
1589.3 
1473.51 
 
-NH Stretching 
-C=N Stretching 
-C-H Stretching 
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 LC-MS CHROMATOGRAM PIA: 
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LC-MS SPECTRUM PIA: 
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NMR SPECTRUM PIA: 
 
Table No :13 INTERPRETATION OF NMR: 
S.No 
 
δ VALUE 
(PPM) 
NUMBER OF 
PROTONS 
 
1 
 
2 
 
3 
 
4. 
 
δ7.3 
 
δ7.5 
 
δ8.1-8.4 
 
δ9.8 
 
2 Protons 
 
1 Protons 
 
2 Protons  
 
1 Proton 
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BIOLOGICAL EVALUATION 
 The anti-tubercular activities of the synthesized compounds were determined by 
MicroplateAlamar Blue Assay method (MABA). The organism used in the study is 
Mycobacterium tuberculosis H37Rv. All the synthesized compounds showed anti-mycobacterial 
activity in varying degrees against the organism tested. The data pertaining to these observations 
are presented. 
TABLE 14: ANTI-TB RESULTS 
 
SL. 
NO 
 
SAMPLE
S 
 
100 
μg/m
l 
 
 
50μg/m
l 
 
 
25 
μg/m
l 
 
12.5 
μg/m
l 
 
6.25 
μg/m
l 
 
3.125 
μg/m
l 
 
1.6 
μg/m
l 
 
0.8 
μg/m
l 
 
1. DCP1 S S S S S S S R 
2. DCP2 S S S R R R R R 
3
. 
DCP3 S S S R R R R R 
4
. 
PIA S S S S R R R R 
 
NOTE:  
S - Sensitive  
R - Resistant  
Strain used: M.tuberculosis(H37 RV strain): ATCC No- 27294.  
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Here are the standard values for the Anti-Tb test which was performed.  
Pyrazinamide- 3.125μg/ml  
Streptomycin- 6.25μg/ml  
Ciprofloxacin-3.125μg/ml 
SNAP SHOT SAMPLE DRUGS : 
 
SNAP SHOT OF STANDARD DRUG PHOTOGRAPH: 
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ACUTE ORAL TOXICITY STUDY: 
Table15 . Acute oral toxicity study: 
 
S.No 
 
PARAMETERS  
 
RESULTS 
 
 
1 
 
Toxic signs 
 
Absent 
 
2 
 
Pre-terminal deaths 
 
Nil 
3 Body weight  
No specific change 
4 Motor activity  
Normal  
5 Tremors   
Absent 
6 Convulsion   
Absent 
7 Straub reaction   
Absent 
8 Righting reflex  
Present  
9 Lacrimation and salivation  
Normal 
10 Unusual vocalization  
Absent 
11 Sedation  
Absent 
12 Body temperature  
Normal 
13 Analgesia   
Absent 
14 Ptosis   
Absent 
15 Diarrhoea  
Absent 
16 Skin colour   
Normal 
17 Respiration   
Normal 
18 Scratching   
Absent 
19 Aggressiveness and restlessness   
Absent 
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       Animals were observed for behavioral signs of toxicity like motor activity, tremor etc., and 
no significant toxic signs were observed during 14 days. The results of the acute toxicological 
studies revealed that the administration of 2 molecules by oral route upto 2000mg/kg/b.w did not 
produce any mortality  it was tolerated. 
CYTOTOXICITY EVALUATION: 
      When campared the compound DCP3 with DCP1,  DCP1 showed decreased IC50 values. 
The drug Rifampicin was used as standard which showed  IC50 value as 113 mcg/ml. 
The table presented below showed IC50 values of DCP1 and DCP3. 
Table :16 CYTOTOXICITY: 
Concentration 
(µ/ml) 
 
DCP1 
 
DCP3 
 
500 
 
52.15 
 
53.59 
 
250 
 
43.68 
 
47.38 
 
125 
 
34.30 
 
41.26 
 
64.5 
 
34.83 
 
27.67 
 
31.25 
 
12.86 
 
16.11 
 
IC50 FROM 
PRISM 
 
 
 
389.7 
 
319.3 
 
     . 
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DISCUSSION 
 According to literature review pyridine was chosen as basic nucleus for antitubercular 
activity. 
 Schiff bases, now a days screened for various pharmacological activities. 
 The synthesized compounds labeled DCP1, DCP2, DCP3  and  PIA  have pyridine 
nucleus which imparts antitubercular activity. 
 3,5-dichloro 4-amino pyridine was taken as primary amine which allowed react with 
various substituted aldehydes , they form Schiff bases. 
 The compound DCP2 showed good docking score which chemically called (E)-1-(4-
chlorophenyl)-N-(3,5-dichloropyridin-4 yl)methanimine  
 If the binding is less, the compound having high binding affinity towards target protein. 
 InhA is enzyme that belong to Fatty Acid Synthase , that found to be one of critical 
enzyme essential for the synthesis of mycolic acid ,which is prerequisite for the formation 
of  Mycobacterial cell wall. 
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SUMMARY 
 Inh A(enoyl-ACP reductase) (2h9i) a critical enzyme for the growth of Mycobacterium 
tuberculosis was chosen for our study after review of literature. 
 Candidate molecules were designed and docked against 2h9i protein using AUTO DOCK 
®1.5.6 software. 
 4 Molecules with good Docking score (lower binding energy) and interactions were 
shortlisted for synthesis. Reaction conditions were optimized. 
 The selected molecules were subjected to toxicity prediction assessment by OSIRIS 
®software.  
 Compounds were synthesized by conventional method and labeled as DCP1, DCP2, 
DCP3, PIA. Purity of the synthesized compounds was ensured by repeated 
recrystallisation and purification by column chromatography. Further the compounds 
were evaluated by TLC and Melting point determination. 
 The characterization of the synthesized compounds was done using Infra-red, Nuclear 
Magnetic Resonance (H1 NMR, C13 NMR) and Mass spectroscopic methods (LC-MS,). 
 The pure compounds were screened for In- Vitro Anti- mycobacterial activity by   
MicroplateAlamar Blue Assay (MABA). All compounds showed significant anti-
mycobacterium activity. 
 The synthesized compound DCP1 were active at 1.6μg/ml, which were comparable into 
the known anti-TB drugs: Pyrazinamide - 3.125μg/ml, Ciprofloxacin - 3.125μg/ml and 
Streptomycin - 6.25μg/ml. The compounds DCP2 and DCP3 were active at 12.5μg/ml. 
 The IC50 values synthesized compounds DCP1 and DCP3 were 389.7 μg/ml  and 319.3 
μg/ml respectively 
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CONCLUSION 
 Our work concludes that our synthesized molecules are effective in inhibiting 
enzymeInhA (enoyl-ACP reductase) (2h9i) which is important for the growth of 
Mycobacterium tuberculosis. 
 All the 4 compounds gave Docking score between -5 to -8 kcal/mol. This goes to prove 
that 2h9i  is a critical enzyme for anti-mycobacterial lactivity. 
 The minimum inhibitory concentration of the 4 synthesized compounds against H37RV 
ranged from 50 to 1.6 μg/ml. 
 Further structural refinement to the structure of the synthesized compounds is expected to 
yield promising molecules against the pathogen Mycobacterium tuberculosis. 
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